Skip to main content

Table 1 Characteristics of patients with middle to lower third rectal adenocarcinoma, receiving neoadjuvant concurrent chemoradiotherapy followed by trans-anal total mesorectal excision assisted by single port laparoscopic surgery

From: Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

  n (%)
Sex
 Male 13 (56.52)
 Female 10 (43.48)
Age, median (range) 63 (31-80)
BMI (kg/m2), median (range) 23.7 (18-32)
ASA  
 ASA score 1 1 (4.35)
 ASA score 2 19 (82.61)
 ASA score 3 3 (13.04)
Distance to anal verge (mm), median (range) 54 (20-80)
Tumor size (mm), median (range) 20 (6-85)
AJCC clinical stages
 Stage II 8 (34.78)
 Stage III 15 (65.22)
Clinical T stage
 cT2 2 (8.70)
 cT3 21 (91.30)
Clinical N stage
 cN0 8 (34.78)
 cN1 11 (47.83)
 cN2 4 (17.39)
Neoadjuvant CCRT 23 (100.00)
  1. ASA American Society of Anesthesiologists, BMI body mass index, CCRT concurrent chemoradiotherapy, AJCC the American Joint Committee on Cancer